Nanobiotix is trading at $28.59, up 7.12%, with the catalyst for the October 22 move remaining unclear. - No new company-specific announcement explaining the move was found; the latest company news located was the October 1 CFO appointment. - A provided pre-market alert cited biotech-sector gains, but available XBI listings show conflicting, weaker pre-market performance, leaving that explanation unconfirmed. - Broader U.S. markets were lower, which does not explain the stock’s rise.